Practical Geriatrics ›› 2026, Vol. 40 ›› Issue (3): 304-308.doi: 10.3969/j.issn.1003-9198.2026.03.016

Previous Articles     Next Articles

Gut microbiota-immune axis: a new perspective on the pathogenesis and therapeutic interventions for postmenopausal osteoporosis

LIU Yue, XUE Qing, LIU Zekun, LIU Bing, QI Hao   

  1. Shanxi Medical University, Taiyuan 030001, China (LIU Yue, XUE Qing, LIU Zekun, LIU Bing);
    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, China (QI Hao)
  • Received:2025-08-05 Published:2026-03-26
  • Contact: QI Hao, Email: qihao@sxmu.edu.cn

Abstract: Postmenopausal osteoporosis (PMO) is a common skeletal disorder among postmenopausal women, significantly impacting their quality of life. Research indicates that the gut microbiota (GM) -immune axis influences the progression of PMO through multiple pathways, and in-depth studies in this area are expected to bring new breakthroughs in the prevention and treatment of osteoporosis. This paper systematically reviews the role of the GM-immune axis in PMO, with a focus on its molecular mechanisms, therapeutic potential, associated controversies, and prospects. Through a comprehensive analysis of relevant literature, we propose that the core direction for future research lies in the precise regulation of the GM-immune axis, such as designing specific probiotics, prebiotics, or drugs to target and modulate the composition and function of GM, thereby providing novel strategies for the treatment of osteoporosis and related diseases. Furthermore, combining GM modulation with traditional anti-osteoporosis medications is expected to enhance therapeutic efficacy and reduce adverse drug reactions.

Key words: postmenopausal osteoporosis, gut microbiota, immune cells, bone metabolism

CLC Number: